In this file
MEDVi QUAD is marketed for erectile dysfunction, not for GLP-1 weight management. Its page lists apomorphine, L-citrulline, sildenafil, and tadalafil in a combination product.
Whether that exact preparation is appropriate requires a clinician to assess the patient and the complete formulation. Evidence or approval for a standalone ingredient does not establish approval, effectiveness, or personal safety for the combined product.
Identify the combination before discussing it
The QUAD marketing page names apomorphine, L-citrulline, sildenafil, and tadalafil. Request the actual prescription ingredients, amounts, route, pharmacy, and instructions rather than deriving directions from an advertisement.
Marketing descriptions of potency or convenience do not establish that the combination is suitable for a particular patient. Ask what evidence supports this exact preparation and what established alternatives were considered.
Separate ingredient evidence from product evidence
MedlinePlus describes sildenafil and tadalafil individually, including warnings and interactions. Those references are useful for a consultation, but they are not studies or approval documents for MEDVi’s combined QUAD formulation.
Do not add another erectile-dysfunction medication or change how you use a prescription based on the assumption that the ingredients work independently. The prescribing professional needs the complete medication list.
Discuss interactions before use
Sildenafil and tadalafil have important interaction warnings, including nitrates used for chest pain. Tell the prescriber about all prescription and nonprescription medicines and any relevant heart or blood-pressure condition. The clinician should determine whether treatment is appropriate.
If you develop chest pain or another emergency, seek urgent medical help and tell the emergency team exactly what you took and when. Do not rely on a routine online support queue to manage an emergency.
Get a specific response plan
Ask what symptoms require stopping the medication and contacting the clinician, and which require emergency care. The individual drug references describe serious concerns including a prolonged erection and sudden changes in vision or hearing; a clinician should explain what to do in your circumstances.
Obtain the dispensing pharmacist’s contact details for formulation, labeling, and storage questions. This publication cannot verify the contents of a shipped product or provide individualized use instructions.
Keep the regulatory discussion in scope
The FDA letter discussed in our MEDVi weight-loss coverage concerns compounded GLP-1 marketing. It should not be represented as a product-specific assessment of QUAD. Equally, approval of a standalone sildenafil or tadalafil product does not confer approval on a different compounded combination.
For more context, read what MEDVi offers and how to assess an online pharmacy.
Keep the connected details together
The MEDVi provider file connects the cost details, support routes, and cancellation questions so that the same plan can be checked from more than one angle.
How do the current offer and product claims address the issues in the FDA letter, and what precise medication would be supplied?
What the research does and does not show
This file follows published documents. It is not a mystery-shopper report, an inspection of a pharmacy, or a guarantee about a future patient experience. The dates and limitations in the source notes matter when a page or policy changes.
A clinician must assess personal treatment suitability. Our pre-purchase questions can help you record the information still needed before accepting an offer.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- MEDVi QUAD: product and ingredient page ↗Provider-published information · Checked September 22, 2026
- MedlinePlus: sildenafil ↗Medical reference · Checked September 22, 2026
- MedlinePlus: tadalafil ↗Medical reference · Checked September 22, 2026
- FDA: MEDVi warning letter, February 20, 2026 ↗Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs ↗Regulatory / public agency · Checked September 22, 2026
- MEDVi: provider, pharmacy, and contact disclosures ↗Provider-published information · Checked September 22, 2026
- FDA BeSafeRx: checking online pharmacies ↗Regulatory / public agency · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026